Alumis (ALMS) Non-Current Deffered Revenue (2025)

Alumis (ALMS) posted quarterly Non-Current Deffered Revenue of $2.6 million for Q4 2025, up 34.31% quarter-over-quarter from $1.9 million in Q3 2025.

Alumis (ALMS) Non-Current Deffered Revenue (2025) Analysis & Trends

Alumis (ALMS) has reported Non-Current Deffered Revenue for 1 consecutive years, with $2.6 million the latest figure, recorded in Q4 2025.

In Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $2.6 million; the TTM figure through Dec 2025 stood at $2.6 million (changed N/A YoY), while the FY2025 annual figure was $2.6 million, changed N/A from the prior year.
Non-Current Deffered Revenue grew to $2.6 million in Q4 2025 per ALMS's latest filing, from $1.9 million in the prior quarter.
Across five years, Non-Current Deffered Revenue topped out at $2.6 million in Q2 2025 and bottomed at $1.9 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	220.40 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Alumis	3.25 Bn	2.75 Bn	-	-

Download Data